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Background: Pathological complete remission (pCR) of estrogen receptor (ER)-positive/human epidermal growth
factor receptor 2 (HER2)-negative breast cancer is rarely achieved after neoadjuvant chemotherapy (NAC). In
addition, the prognostic value of pCR for this breast cancer subtype is limited. We explored whether response
evaluation by magnetic resonance imaging (MRI) is associated with recurrence-free survival after NAC in ER-
positive/HER2-negative breast cancer.
Methods: MRI examinations were performed in 272 women with ER-positive/HER2-negative breast cancer before,
during and after NAC. MRI interpretation included lesion morphology at baseline, changes in morphology and size,
and contrast uptake kinetics. These MRI features, clinical characteristics and final pathology were correlated with
recurrence-free survival.
Results: The median follow up time was 41 months. There were 35 women with events, including 19 breast-cancer-
related deaths. On multivariable analysis, age younger than 50 years (hazard ratio (HR) = 2.55, 95 % confidence interval
(CI) 1.3, 5.02, p = 0.007), radiological complete response after NAC (HR = 14.11, CI 1.81, 1818; p = 0.006) and smaller
diameters of washout/plateau enhancement at MRI after NAC (HR = 1.02, CI 1.00, 1.04, p = 0.036) were independently
associated with best recurrence-free survival. Pathological response was not significant; HR = 2.12, CI 0.86, 4.64, p = 0.096.
Conclusions: MRI after NAC in ER-positive/HER2-negative tumors may be predictive of recurrence-free survival. A
radiological complete response at MRI after NAC is associated with an excellent prognosis.
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Neoadjuvant chemotherapy (NAC) for breast cancer has
been shown to be equally effective as postoperative
chemotherapy in terms of disease-free and overall sur-
vival [1–4]. Several markers are routinely employed to
predict treatment outcome and to select therapy [5–7].
The most frequently used include the estrogen receptor* Correspondence: c.loo@nki.nl
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dermal growth factor receptor 2 (HER2). Three major
breast cancer subtypes are easily distinguished by immu-
nohistochemical assessment (IHC): triple-negative (ER,
PR and HER2-negative), HER2-positive (HER2-positive
(ER and PR may be positive or negative)) and ER-
positive/HER2-negative (ER-positive, HER2-negative (PR
may be positive or negative)) [8, 9]. These immunohisto-
chemical subtypes correspond roughly to the molecular
subtypes, basal-like, HER2-enriched and luminal, re-
spectively [10]. Subtyping of typically heterogeneous
breast cancer in these three groups may improvele is distributed under the terms of the Creative Commons Attribution 4.0
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result in optimized strategies for patient-tailored treat-
ment [11, 12].
Even within these subgroups, the response to and out-
come after chemotherapy vary widely. Pathologically
confirmed complete remission (pCR) or minimal disease
[13, 14] after chemotherapy is associated with disease-
free and overall survival [1, 2, 15, 16]. More recently,
however, it has been shown that this relationship is ab-
sent for luminal A tumors [17], which comprise approxi-
mately half of the tumors that express the ER but which
do not contain a HER2 gene amplification. Nevertheless,
pCR is often used as a surrogate marker to predict long-
term outcome in this subgroup. Of patients with ER-
positive/HER2-negative tumors only a small fraction will
achieve pCR, while the prognosis is better than that of
triple-negative breast cancer [17]. Therefore pCR after
NAC in ER-positive/HER2-negative tumors is certainly
not a practical prognostic indicator. It is possible that
dynamic contrast-enhanced magnetic resonance imaging
(MRI), which visualizes functional properties of the
tumor such as those associated with angiogenesis, may
be used as a practical prognostic indicator.
The benefit of MRI over other imaging modalities for
monitoring response during and after NAC has been ex-
tensively reported [18–21]. Also prediction of patho-
logical response after NAC by MRI has been extensively
studied [22–24]. A recent published study evaluated
volumetric MRI for predicting recurrence-free survival
after NAC in patients with breast cancer [25]. However,
the role of MRI after NAC in predicting survival in
patients with ER-positive/HER-2negative tumors in
particular has not yet been completely assessed. The
purpose of this study was to explore whether MRI is
associated with recurrence-free survival after neoadju-




Patients between 18 and 70 years of age with pathologic-
ally proven invasive ER-positive/HER2-negative breast
cancer >3 cm in size and/or at least one tumor-positive
lymph node were offered NAC. All patients received
NAC between January 2000 and June 2012, and all either
took part in a single-institution clinical trial (approved
by the Medical Research Ethics Committee of the
Netherlands Cancer Institute), or were treated off study
according to the standard arm of the trial [26, 27]. The
institutional review board had approved the study proto-
cols and informed consent was obtained from all
patients. Only patients with ER-positive/HER2-negative
tumors based on immunohistochemical assessment
without a prior history of breast cancer were included inthis analysis. Only patients who had undergone MRI be-
fore (baseline), during (after three courses) and after
NAC and who underwent surgery after NAC were
included.
Treatment
Four different regimens of NAC were employed [26, 27].
Between 2000 and 2004 patients were randomized to re-
ceive either six cycles of treatment AC or six cycles of
treatment AD, with AC being considered as standard
treatment. AC consisted of doxorubicin 60 mg/m2 and
cyclophosphamide 600 mg/m2 every three weeks,
whereas patients in the AD arm were treated with six
cycles of doxorubicin 50 mg/m2 and docetaxel 75 mg/
m2. After 2004, patients started with three courses of
ddAC (doxorubicin 60 mg/ m−2 and cyclophosphamide
600 mg/ m−2 on day 1, every 14 days, with PEG-
filgrastim on day 2). When an unfavorable response was
noted on MRI (defined as a reduction <25 % in the
largest diameter of the tumor plateau/washout enhance-
ment [28]) after three courses of treatment, chemother-
apy was switched to a (theoretically) non-cross-resistant
regimen. In such a case, three courses of ddAC were
followed by three courses of docetaxel and capecitabine
(DC, docetaxel 75 mg/ m−2 on day 1, every 21 days and
capecitabine 2 × 1000 mg/ m−2 on days 1–14). In the
case of a favourable response on MRI, chemotherapy
was continued with three further courses of ddAC.
After the last course of chemotherapy, all patients
underwent surgery (breast-conserving surgery or
mastectomy with or without axillary lymph node dis-
section), post-operative external beam radiation ther-
apy, and adjuvant endocrine therapy, according to
standard guidelines.
MRI and evaluation
Initially MRI was performed on a 1.5 T Magnetom Vi-
sion scanner with a dedicated bilateral phased array
breast coil (Siemens, Erlangen, Germany). From April
2007 MRI was performed on a 3.0 T Achieva scanner
with a dedicated 7-element sense breast coil (Philips
Medical Systems, Best, The Netherlands). Images were
acquired with the patient in the prone position and with
both breasts imaged simultaneously. The standard dy-
namic protocol started with an unenhanced coronal 3D
fast field echo (FFE) (thrive) sense T1-weighted se-
quence. A bolus (14 mL) of contrast containing gadolin-
ium (0.1 mmol/kg) was administered intravenously at 3
mL/s using a power injector followed by a bolus of 30
mL of saline solution. Subsequently, dynamic imaging
was performed in five consecutive series at 90-s inter-
vals. The voxel size was 1.21 × 1.21 × 1.69 mm3 (1.5 T)
or 1.1 × 1.1 × 1.2 mm3 (3.0 T). The following scanning
parameters were used: acquisition time 90 s (1.5 T and
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T) or 4.4/2.3 (3.0 T); flip angle 20° (1.5 T) or 10° (3.0 T);
field of view (FOV) 310 (1.5 T) or 360 (3.0 T).
Breast MR images were interpreted using a viewing
station that permitted simultaneous viewing of two
series reformatted and linked in three orthogonal direc-
tions [29]. The viewing station displays all imaging series
(unenhanced and contrast-enhanced), subtraction im-
ages at 90-s intervals and maximum intensity projection
(MIP) of both breasts. The displayed images were also
color coded, representing different levels and curve types
of enhancement. Specifically, the color indicated the
shape of the time-signal intensity (contrast enhance-
ment) curve at each pixel location [30]: type I (i.e., per-
sistent enhancement >10 % after the first post-contrast
image), type II (i.e., plateau enhancement between −10 %
and +10 % during late enhancement), and type III (i.e.,
washout kinetics resulting in >10 % signal decrease dur-
ing late enhancement) [30]. These colors were coded
yellow, light red and dark red, respectively, where initial
enhancement (90 s) equaled or exceeded 100 % and
green, light blue and dark blue, respectively, where initial
enhancement was between 50 % and 100 %. The viewing
station was developed in close collaboration with the
breast radiologists at the Netherlands Cancer Institute.
The radiologists have been using the system since 2000.
The MR images were assessed by four breast radiolo-
gists, who were unaware of the outcome. The patients
were randomly distributed among the radiologists for as-
sessment. The MR images before (baseline), during and
after chemotherapy were analyzed by the same radiolo-
gist in one session to ensure interpretive consistency.
Temporal and morphologic characteristics of contrast
uptake were scored as previously described [28]. In
short, tumor extent, morphology and relative en-
hancement were assessed during initial enhancement
(90 s) and late enhancement (450 s) on all subsequent
MRI scans.
The extent of the tumor was assessed by its largest
diameter in three reformatted planes (sagittal, axial and
coronal) at initial and at late (washout/plateau) enhance-
ment separately. If a non-mass (diffuse) enhancement or
multifocal disease was visible, the total area including
non-enhancing breast tissue between lesions was mea-
sured on MIP images. The largest value of the three di-
ameters was recorded. The percentage difference in
largest tumor diameter between subsequent MRI scans
was also assessed, both at initial and at late enhance-
ment. Supported by the color coding, the area within the
tumor with the strongest contrast uptake at initial and
at late enhancement was determined. Measurement of
the signal intensity (initial and late enhancement) was
performed manually by placing a region of interest in
the most malignant area (dark red) and moving thecursor in this area to find the most malignant values, in
real time (in percentages). Morphology of the enhancing
tumor was scored in three groups: unifocal mass, multi-
focal mass and non-mass (diffuse) enhancement [31].
On MRI during and after NAC the pattern of tumor re-
duction was denoted in five categories: shrinking mass,
diffuse decrease, reduction to small foci, no enhance-
ment and no change.
Complete absence of contrast enhancement in the ori-
ginal tumor bed on MRI after NAC was defined as
radiological complete response. Consequently, evidence
of small enhancing foci in the original tumor bed was
considered as residual enhancing tumor.
Histopathologic analysis
Prior to NAC at least three 14-G ultrasound-guided core
biopsies of the breast tumor were taken. Subsequently,
most tumors were marked with a radiopaque marker.
ER and PR status were determined by immunohisto-
chemical assessment and considered positive if ≥10 % of
nuclei stained positive, and HER2 status was assessed by
scoring the intensity of membrane staining. Tumors with
a score of 3+ (strong homogeneous staining) were consid-
ered positive. In the case of 2+ scores (moderate homoge-
neous staining) chromogenic in situ hybridization (CISH)
was used to determine HER2 amplification (gene copy
number of six or more per tumor cell). For this study ER-
positive/HER2-negative tumors were selected.
Pathologic response
Three common definitions of pCR were used: (1) no re-
sidual invasive tumor in the breast (ypT0/is) [15, 32], (2)
no residual invasive tumor in the breast or axilla (ypT0/
isN0) [33] and (3) a near-complete response, indicating
the presence of only a small number of scattered tumor
cells in the breast (ypT <mic) [14].
Statistical analysis
The primary endpoint was recurrence-free survival
(RFS), defined according to the standardization of events
and endpoints (STEEP) criteria [34]. According to this
definition an event is either a local, regional or distant
breast cancer recurrence or death due to any cause. Sec-
ond primaries (including contralateral breast cancer)
were not considered an event. The final data were
collected in September 2014, and patients for whom no
event had occurred were censored at the last date of
being seen alive.
The median length of follow up was calculated using
the reverse Kaplan-Meier approach. Patient characteris-
tics are presented in tables as medians (percentiles) for
continuous variables and frequencies for categorical
variables. All clinical variables were analyzed as categor-
ical predictors (Table 1). The MRI characteristics were
Table 1 Univariable Cox proportional hazard analysis of relationship between clinical variables and recurrence-free survival
Recurrence-free survival
Variable Number of patients Number of events P value Hazard ratio 95 % CI
Tumor (T) stage prior to NAC 0.731
T1 28 1
T2 149 19 2.42 0.32, 18.16
T3 79 12 2.7 0.35, 20.99
T4 16 3 2.91 0.30, 28.09
Node (N) stage prior to NAC 0.558
Negative 55 6
Positive 217 29 1.29 0.54, 3.11
Clinical stage 0.847
II 185 24
III 86 11 0.93 0.46, 1.91
Unknown 1
Age 0.008
≤50 years at diagnosis 177 17
>50 years at diagnosis 95 18 2.49 1.28, 4.85
Menopausal status 0.017
Premenopausal 161 15
Perimenopausal 16 2 1.42 0.32, 6.24
Postmenopausal 91 18 2.74 1.38, 5.46
Unknown 4
Histologya 0.835
Adenocarcinoma, n 18 3
Ductal carcinoma 207 27 1.39 0.42, 4.62
Lobular carcinoma 39 4 0.93 0.21, 4.16
Other 8 1 1.08 0.11, 10.42
Progesterone receptora 0.199
Negative 76 13




Moderate 117 16 3.57 0.8, 15.93




AC-CD 77 8 1.23 0.54, 2.83
AD 14 4 0.79 0.25, 2.55
CD 13 3 1.33 0.39, 4.51
Unknown 1
Pathologic response
ypT0/isypN0: No 261 35 0.41
yes 11 0 0.37 0, −b
Loo et al. Breast Cancer Research  (2016) 18:82 Page 4 of 12
Table 1 Univariable Cox proportional hazard analysis of relationship between clinical variables and recurrence-free survival
(Continued)
ypT0/is: No 251 34 0.29
yes 21 1 0.39 0.05, 2.88
ypT <mic: No 221 28 0.91
yes 51 7 0.95 0.42, 0.91
Univariable Cox model for clinical and pathologic parameters of recurrence-free survival. aDetermined on pre-chemotherapy ultrasound-guided biopsy. b− CI boundary
could not be estimated. NAC neoadjuvant chemotherapy, CI confidence interval , (dd)AC (dose-dense) cyclophosphamide and doxorubcin, CD capecitabine and
docetaxel, AD doxorubcin and docetaxel, ypT0/isypN0 no residual invasive tumor in breast and axilla, ypT0/is no residual invasive tumor in the breast,
ypT <mic few scattered tumor cells in the breast. Numbers in bold are significant values
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variables (Table 3). For the categorical predictors, the
first mentioned category was taken as a reference and
the hazard ratio (HR) compares the subsequent categor-
ies to the reference. For the continuous predictors, the
HR represents a change in hazard for one unit change in
the predictor.
The clinical and MRI characteristics were first tested
for association with the outcome in univariable Cox
models. Next, the significant and clinically relevant pa-
rameters were analyzed jointly in a multivariable Cox
model. When at least one of the analyzed subgroups had
no events, the Cox regression with Firth’s penalized like-
lihood was used for the estimation of the hazard ratios.
Confidence intervals were then computed using profile
likelihood. This technique has been implemented in the
R package coxphf.
The optimal cut points and their significance for the
continuous variables were estimated using maximally se-
lected rank statistics as implemented in the R package
maxstat. Variables for which the p value was <0.05 were
considered significant. The final model was built by
combining statistical evidence (significant p values) and
clinical relevance (age, pathological response). All statis-
tical analyses were performed using R software (version
3.1.0) or SPSS (version 20).
Results
Between January 2000 and June 2012 428 patients with
ER-positive/HER2-negative breast cancer were registered
in the NAC breast database of our institute. Of these,
279 patients had response evaluation with MRI (before,
during and after), underwent surgery and had no distant
metastasis. Seven patients were excluded; four because
of a history of breast cancer, two because of technically
inadequate MRI, and one patient because she was found
to have HER2-positive breast cancer. The majority of the
272 women were premenopausal, had invasive ductal
carcinoma, positive nodal stage prior to NAC and tumor
stage T2 tumors (Table 1). The median (range) of the
measurements of the largest diameter of the initial
tumor on MRI was 4.3 cm (1.0–11.5). The median ageat diagnosis was 47 years (range 19–68). The median
follow-up time was 41 months (3.4 years).
There were 35 women with an event; 31 women had
distant metastases, 2 had additional local/regional recur-
rence, one only a local/regional recurrence and one pa-
tient died without any recurrence reported. There were
20 deaths: 19 breast-cancer-related deaths and 1 death
due to another malignancy. The RFS for the study group
is shown in Fig. 1.
Univariable Cox model for clinical and pathological
parameters
Among the clinical and pathological parameters, post-
menopausal status (HR = 2.73, p = 0.04) and age over 50
years (HR = 2.49, p = 0.01) were associated with worse
RFS (Table 1). pCR, according to any investigated defin-
ition, was not associated with improved RFS (Table 1,
Fig. 2). Twenty-one patients (7.7 %) achieved an ypT0/is
of the primary tumor after NAC. Only one recurrence
was found in this group (p = 0.29). Eleven (4 %) patients
had no residual invasive tumor in the breast or axilla
(ypT0/isypN0) after NAC. In this group, no events oc-
curred (p = 0.41). Also, a near pCR (a few scattered
tumor cells in the breast (ypT <mic)) was observed in
51 patients (seven events), which was not associated
with RFS (p = 0.91). Kaplan-Meier curves for the patho-
logic response are shown in Fig. 2.
Univariable Cox model for MRI parameters
No tumor enhancement (i.e., a radiological complete re-
sponse) after NAC (HR = 12.81, p = 0.004) was signifi-
cantly associated with superior RFS (Table 2). Forty-four
of the 272 patients (16.2 %) achieved a radiological
complete response after NAC as identified on MRI. No
events were found in this group. Kaplan-Meier curves
for patients with ER-positive/HER2-negative breast can-
cer show significant difference in RFS between patients
with a radiological complete response and those with re-
sidual enhancement on MRI (log-rank p = 0.012; Fig. 3).
Also the largest diameter of the region with washout/
plateau (late) enhancement was associated with RFS on
baseline MRI (HR = 1.017, p = 0.027), during NAC (HR =
Table 2 Univariable Cox proportional hazard analysis of relationship between MRI variables and recurrence-free survival
Number of Number of Recurrence free survival
Variable patients events P value Hazard ratio 95 % CI
Lesion morphology baseline MRI 0.612
Mass unifocal 91 10
Mass multifocal 96 12 1.29 0.71, 3.70
Non mass (diffuse) 77 13 1.60 0.57, 3.01
Mass and non mass 8 0 4.38 0.03, 41.66
Pattern of reduction at MRI after NAC 0.029
No change 23 4
Shrinking mass 96 10 0.56 0.19, 1.89
Diffuse decrease 56 10 0.78 0.27, 2.64
Small foci 53 11 0.95 0.34, 3.19
No enhancement 44 0 0.06 0, 0.53
Dynamic curve type after NAC 0.008
No enhancement 44 0
Continuous 89 16 13.54 1.83, 1728.03
Plateau 82 5 7.46 0.84, 980.87
Washout 57 14 17.59 2.35, 2248.46
Radiological complete response 0.004
Yes 44 0
No 228 35 12.81 –a, 1621.10
RECIST evaluation MRI initial after NAC - baseline 0.009
No enhancement after NAC 44 0
Part Rem (LD initial↓ ≥30 %) 154 23 11.63 –a, 1477.68
NR (LD initial↓ <30 %) 74 12 16.53 2.17, 2119.55
RECIST evaluation MRI initial after NAC – during 0.037
No enhancement during and after NAC 10 0
No enhancement after NAC 36 0 0.44 0, 80.78
Part Rem (LD initial↓ ≥30 %) 82 11 3.99 0.52, 513.45
NR (LD initial ↓ <30 %) 144 24 4.95 0.68, 629.57
RECIST evaluation MRI late after NAC - baseline 0.05
No washout/plateau baseline and after NAC 8 0
No washout/plateau after NAC 136 17 3.08 0.41, 394.53
Part Rem (LD late ↓ ≥30 %) 93 12 3.54 0.46, 455.8
NR (LD late ↓ <30 %) 35 6 11.57 1.31, 1525.99
RECIST evaluation MRI late after NAC - during 0.46
No plateau/washout during and after NAC 61 6
No plateau/washout after NAC 84 11 1.17 0.43, 3.17
Part Rem (LD late ↓ ≥30 %) 58 9 1.65 0.59, 4.64
NR (LD late ↓ <30 %) 69 9 2.08 0.74, 5.87
Univariable Cox proportional hazard analysis of magnetic resonance imaging (MRI) variables with recurrence-free survival. aCI boundary could not be estimated. CI
confidence interval, LD largest diameter, Part Rem partial remission, initial enhancement 90 s, late washout/plateau enhancement 450 s, MRI magnetic resonance
imaging, NAC neoadjuvant chemotherapy, NR non responder, RECIST response evaluation criteria in solid tumors. Arrow (↓) indicates decrease. Numbers in bold
are significant values
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Table 3 Univariable Cox proportional hazard analysis of relationship between continuous MRI variables and recurrence-free survival
Recurrence-free survival
MRI variable Median P value Hazard ratio 95 % CI
Baseline (before NAC)
Largest diameter MIP/initial enhancement (90 s) 43 mm 0.238 1,009 0.994, 1.024
Largest diameter plateau/washout enhancement (450 s) 33 mm 0.027 1,017 1.002, 1.033
Initial enhancement (90 s) % 152 % 0.326 0.997 0.99, 1.003
Late enhancement (450 s) % −13 % 0.947 0.999 0.967, 1.032
During NAC
Largest diameter MIP/initial enhancement (90s) 30 mm 0.155 1,011 0.996, 1.026
Largest diameter plateau/washout enhancement (450 s) 17 mm 0.006 1,024 1.007, 1.041
Initial enhancement % 135 % 0.993 1.00 0.995, 1.005
Late enhancement % −4 % 0.600 0.995 0.975, 1.015
After NAC
Largest diameter MIP/initial enhancement (90s)a 22 mm 0.140 1.01 1.00, 1.03
Largest diameter plateau/washout enhancement (450 s) 0 mm 0.003 1.03 1.01, 1.051
Initial enhancement % 100 % 0.057 1,005 1.00, 1.011
Late enhancement % 9 % 0.815 0.998 0.983, 1.014
Percent change after NAC - baseline NAC %
Largest diameter MIP/initial enhancement (90 s)b −40 % 0.280 1.01 0.99, 1.02
Largest diameter plateau/washout enhancement (450 s)c −100 % 0.021 1,013 1.002, 1.024
Percent change after NAC - during NAC %
Largest diameter MIP/initial enhancement (90 s) mmb −30 % 0.290 1.01 0.99, 1.02
Largest diameter plateau/washout enhancement (450 s)c −61 % 0.066 1,008 0.999, 1.017
aPatients with largest diameter 0 mm were excluded; bpatients with change −100 % were excluded; cpatients without washout/plateau on both scans were
excluded. MRI magnetic resonance imaging, CI confidence interval, NAC neoadjuvant chemotherapy, MIP maximum intensity projection. Numbers in bold
are significant
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(Table 3). The most significant cut off for the largest diam-
eter of washout/plateau enhancement after NAC was esti-
mated for the value 22 mm. Log-rank test p value <0.001
(Fig. 4). In addition, the percent change in the largest
diameter of the region with washout/plateau enhancement
between baseline and after NAC (HR = 1.013, p = 0.021)
was associated with RFS (Table 3).
Multivariable analysis
In the multivariable analysis we fitted a Cox model in-
cluding radiological complete response after NAC, the
largest diameter of washout/plateau on MRI after NAC,
the patient’s age and pathological response (ypT <
mic).The first three predictors remained statistically
significant with HR of 14.11 (1.8–1818, p = 0.006), 1.02
(1.00–1.04, p = 0.036) and 2.55 (1.3–5.02, p = 0.007), re-
spectively. Pathological response did not remain signifi-
cant; HR = 2.12 (0.86–4.64, p = 0.096).
Discussion
In a series of 272 consecutive patients with luminal (ER-
positive/HER2-negative) breast cancer, radiological completeremission assessed on MRI after NAC was associated with
significantly improved RFS after NAC. All of the 44 patients
(16 %) with radiological complete response remained free of
disease during follow up.
This finding may be of clinical importance. Luminal
breast cancer is the most common breast cancer and rep-
resents approximately 2/3 of all cases. Patients with lu-
minal tumors only rarely achieve pCR. In this study, only
8 % (21/272) achieved pCR in the breast and even fewer
patients (4 % (11/272)), achieved pCR in the breast and
axilla. In our study neither pCR (i.e., ypT0is or ypT0isN0)
nor near-pCR was predictive of improved RFS. These find-
ings are in accordance with previously published work
[17]. Also other studies showed that pCR is not a suitable
surrogate endpoint for patients with ER-positive/HER2-
negative grade 1 or 2 (luminal A) breast cancer [35, 36].
We investigated the potential of MRI to predict
recurrence-free survival. MRI after completion of chemo-
therapy was found to be of particular prognostic value in
the current study. Apparently, the lack of enhancement
on MRI, which provides information about functional
properties of the tumor, is associated with prognosis in
slowly proliferating tumors, but pCR is not.
Fig. 1 Recurrence-free survival among 272 patients with estrogen
receptor (ER)-positive/human epidermal growth factor receptor 2
(HER2)-negative breast cancer after neoadjuvant chemotherapy (solid
line), and the 95 % confidence interval. Numbers of patients at risk
are shown above the x-axis
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NAC as a diagnostic tool to serve as a surrogate for final
pathology [37–39]. The majority of studies have focused
on the correlation between tumor size as assessed by
MRI and that identified on pathology assessment to val-
idate MRI as a tool to detect residual disease and to
guide surgical planning. In terms of tumor size, MRI
may underestimate or overestimate compared to path-
ology assessment, resulting in false-negative and false-
positive results [40, 41]. Other studies have shown that a
complete response after neoadjuvant chemotherapy
identified on MRI is associated with the presence of re-
sidual tumor pathology assessment in 26–56 % of cases
[26, 42]. More recent studies have indicated that the ac-
curacy of MRI in estimating tumor size after neoadju-
vant chemotherapy varies with breast cancer subtype
and tumor morphology [22, 24, 39, 43]. The best accur-
acy is achieved in HER2-positive and triple-negative tu-
mors [22, 24, 39]. We found that a radiological complete
response in ER-positive breast cancer is associated with
an excellent prognosis. However in 36 % (16/44) of these
cases, there was (microscopic) residual tumor on the
final pathology assessment.
We used a very strict definition of a radiological
complete response in which even small enhancing foci
in the original tumor bed are considered as residual
tumor. Especially in diffuse tumors (non-mass enhance-
ment) that disintegrate into (very) small foci the radio-
logical assessment can be challenging and in clinicalpractice small enhancing foci may occasionally be inter-
preted incorrectly as a radiological complete response.
We have observed such interpretation discrepancies be-
tween the retrospective dedicated review of our study
and the clinical routine MRI assessment. For future val-
idation studies it will be important to maintain the strict
definition of radiological complete response.
The policy of changing the chemotherapy regimen in
the case of an unfavorable MRI response during NAC
could have led to an increase in the (radiological)
complete remission rate in our study. This was certainly
the objective of the policy, but whether this really suc-
ceeded needs to be further studied in controlled trials.
We assumed that a larger reduction in tumor size on
MRI could correlate with a smaller volume of residual
tumor, but it could also serve as a measure of chemo-
therapy sensitivity. The latter could be critically import-
ant for the likelihood that micro-metastatic disease has
been eradicated or reduced, which is the primary object-
ive of NAC. The differences between radiological
complete remission (CR) and pCR in this respect, in-
clude the more frequent occurrence of radiological CR
in this type of tumor and perhaps the higher likelihood
of radiological CR in tumor subtypes that tend to recur
less often or later than others. Although a detailed sub-
group analysis could not be performed due to the lim-
ited number of patients, there was no indication that the
association between radiological CR and RFS was differ-
ent for different chemotherapy regimens or between pa-
tients who did and those who did not cross over to a
different chemotherapy regimen (Table 1).
The value of MRI with or without prognostic markers
such as those derived from pathology assessment is yet
unclear when it comes to predicting disease-free survival
of patients with ER-positive/HER2-negative breast can-
cer. A few studies have investigated the predictive role of
MRI in breast cancer survival after NAC without using a
distinction in subgroups [44–46]. In a relatively small
study group of 58 patients with a short median follow
up of 33 months, Partridge et al. showed that initial MRI
volume before NAC, and final change in MRI volume
were significant predictors of RFS [44]. Yi et al. evalu-
ated 158 breast cancer patients with MRI before and
after NAC. They concluded that a smaller reduction in
tumor volume and a smaller reduction in washout com-
ponent, assessed with computer-aided evaluation, were
associated with worse RFS [45].
Jafri et al. evaluated the optimal threshold for measur-
ing functional tumor volume in 64 patients. They con-
cluded that functional tumor volume is able to predict
RFS and could be used as a biomarker [46]. These three
studies did not report how many patients achieved
radiological or clinical complete response on MRI, nor





Fig. 2 Kaplan-Meier curves for recurrence-free survival (RFS) in relation to pathologic response after neoadjuvant chemotherapy in patients with
estrogen-receptor-positive tumors. The solid line indicates patients with no response. Numbers of patients at risk for each group are shown above the x-
axis. a Blue line indicates no residual invasive tumor in the breast and axilla (ypT0N0) (p = 0.41); b blue line indicates no residual invasive tumor in the breast
(ypT0/is) (p = 0.29); c blue line indicates only a small number of scattered tumor cells in the breast (ypT <mic, i.e., a near-complete response) (p= 0.91)
Loo et al. Breast Cancer Research  (2016) 18:82 Page 9 of 12A more recent published study (ACRIN 6657) noted
that functional tumor volume (tumor volume percent
enhancement >70 %) after NAC is a strong predictor of
RFS in breast cancer [25]. Their Kaplan-Meier analyses
performed by subtype suggest that the ability of func-
tional tumor volume to discriminate differences differs
per breast cancer subtype. After NAC, a greater RFS
separation was found in 78 ER-positive/HER2-negative
and 41 HER2-positive breast cancers than in the wholegroup. Instead of volumetric measurements, we assessed
the largest diameter at initial (MIP, 90 s) and late (wash-
out/plateau) enhancement on MRI. In accordance with
Yi et al. we found that the largest diameter of washout/
plateau and the change in this diameter are significantly
associated with RFS in our subset of ER-positive breast
cancer. However, in daily clinical practice a radiological
complete response is a more straightforward and poten-
tially a more reproducible measure to identify patients
Log-rank p=0.012
Log-rank p=0.012
Fig. 3 Kaplan-Meier curves for recurrence-free survival (RFS) of
patients with estrogen-receptor-positive tumors based on radiological
complete response (black line no enhancement) and those with
residual enhancement (blue line) identified on magnetic resonance
imaging after neoadjuvant chemotherapy. Log-rank test p = 0.012.
Numbers of patients at risk in each group are shown above the x-axis
Loo et al. Breast Cancer Research  (2016) 18:82 Page 10 of 12with ER-positive/HER2-negative breast cancer who have
a good prognosis. On the other hand, in patients with
residual enhancement on MRI, and who thus may have
a less favorable prognosis, the largest diameter of wash-
out/plateau enhancement may be used to decide ifLog-rank p < 0.001
Fig. 4 Kaplan Meier curve for recurrence-free survival of patients with
ER-positive tumors with washout/plateau enhancement smaller than
22 mm (black line) and those with a diameter of washout/plateau
larger than 22 mm (blue line) after neoadjuvant chemotherapy on
magnetic resonance imaging. LD largest diameter. Numbers of patients
at risk in each group are shown above the x-axisadditional chemotherapy is required. For this study
population the most significant cut off was estimated for
a largest diameter of 22 mm. However, before we can ac-
tually use this value we need to validate this in a larger
study group, preferably with longer follow up.
Our study has some limitations. These involve poten-
tial suboptimal selection of groups and differences in
chemotherapy regimens. The study ran for an extensive
period of time (2000–2012). During this time, the 1.5 T
MRI scanner was replaced by a 3 T scanner, and the
MRI scan protocol was amended to standard clinical
care. Care was taken to align the MRI protocols over
time between 1.5 T and 3 T as much as possible, but
minor differences could not be avoided in voxel size and
FOV. During the study period the temporal resolution
and methods used to analyze the images remained un-
changed. Although we have no indication that this is the
case, one can never be certain that small differences in
scan protocols may affect the results in some way. This
is a limitation that is difficult to avoid in longer-running
radiological studies such as those presented here, given
the rapid developments in MRI technology that inevit-
ably find their way into daily clinical practice. Nonethe-
less, despite these differences, we were still able to
demonstrate significant associations. In addition, the
MRI measurements were performed interactively on the
basis of automatically calculated color overlay images by
different radiologists. Even though the measurements
(largest diameter, ROI placement for relative enhance-
ment percentage) were carried out carefully by dedicated
breast radiologists and according to protocol this man-
ual procedure is to a certain extent subjective and can
lead to potential bias. Although more recent methods of
volumetric assessment may further reduce subjectivity, it
is difficult to avoid it altogether due to empirical adjust-
ments of parameters such as percent-enhancement
thresholds and placement of the region of interest [25].
Although the total study group is relatively large, only
35 recurrences occurred during a follow-up time that is
relatively brief for ER-positive/HER2-negative (luminal)
tumors. This resulted in wide confidence intervals for
the hazard ratios. In this study the tumor grade deter-
mined on the biopsy was known in only 177 (65 %) pa-
tients. As a result we were not able to allow additional
stratification in luminal A and luminal B tumors. Ideally,
subtyping would also have been based on gene expres-
sion rather than on immunohistochemical assessment,
and the median follow up would have been longer, with
more recurrences available for analysis. On the other
hand, the predictive effect of a radiologic complete re-
sponse may be especially clear in the first 5 years after
NAC. The Oxford overview has shown that chemother-
apy prevents recurrences within the first 5 years, while
the preventive effect of endocrine treatment, which is at
Loo et al. Breast Cancer Research  (2016) 18:82 Page 11 of 12least as important in luminal tumors, extends beyond 10
years [47]. As a result, effective chemotherapy may pre-
vent early relapse, seen after limited follow up, when the
endocrine treatment effect is not yet dominant.
Another limitation is that different dedicated breast ra-
diologists in a single institution using strict criteria
assessed the results. As a result, we were not able to
evaluate inter-observer or intra-observer variability. Fur-
ther exploration with longer follow up and an external
validation cohort will be useful to validate our results.
Conclusions
In conclusion, radiologic complete response on MRI
after NAC in patients with ER-positive/HER2-negative
tumors is associated with an excellent outcome. In the
case of residual enhancement on MRI after NAC, the
largest diameter of late enhancement may be helpful to
identify patients who may need additional treatment.
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